There are 807 resources available
LBA7 - A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
Presenter: Byoung Chul Cho
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA7
Presenter: Ben Solomon
Session: Presidential Symposium
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Solange Peters
Session: Presidential Symposium
Resources:
Slides
Webcast
LBA8 - Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
Presenter: Tony S.K. Mok
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8
Presenter: Solange Peters
Session: Presidential Symposium
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Solange Peters
Session: Presidential Symposium
Resources:
Slides
Webcast
Welcome and introduction
Presenter: Alvin Wong
Session: Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin
Resources:
Webcast
Treating la/mUC: Unmet needs and the rapidly evolving landscape
Presenter: Alvin Wong
Session: Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin
Resources:
Webcast
Spotlight on the clinical value of enfortumab vedotin in la/mUC: A review of the EV-301 core data
Presenter: Thomas Powles
Session: Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin
Resources:
Webcast
Patient management strategies for la/mUC treatment with enfortumab vedotin: A clinical case discussion
Presenter: Terence Friedlander
Session: Astellas Pharma - The future of advanced urothelial carcinoma treatment is here: A focus on enfortumab vedotin
Resources:
Webcast